UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 130

Sortiert nach

Heterogeneity of TP53 Mutations and P53 Protein Residual Function in Cancer: Does It Matter?

Frontiers in oncology, 2020-10, Vol.10, p.593383-593383

2020

Volltextzugriff (PDF)

The fading guardian: clinical relevance of TP53 null mutation in high-grade serous ovarian cancers

Frontiers in immunology, 2023-08, Vol.14, p.1221605

2023

Volltextzugriff (PDF)

Time to first treatment and P53 dysfunction in chronic lymphocytic leukaemia: results of the O-CLL1 study in early stage patients

Scientific reports, 2020-10, Vol.10 (1), p.18427, Article 18427

2020

Volltextzugriff (PDF)

Mutant p53K120R expression enables a partial capacity to modulate metabolism

Frontiers in genetics, 2022-09, Vol.13

2022

Volltextzugriff (PDF)

PRIMA-1 induces autophagy in cancer cells carrying mutant or wild type p53

Biochimica et biophysica acta, 2013-08, Vol.1833 (8), p.1904-1913

2013

Volltextzugriff (PDF)

Structure of p73 DNA-binding domain tetramer modulates p73 transactivation

Proceedings of the National Academy of Sciences - PNAS, 2012-04, Vol.109 (16), p.6066-6071

2012

Volltextzugriff (PDF)

P53 family members modulate the expression of PRODH, but not PRODH2, via intronic p53 response elements

PloS one, 2013-07, Vol.8 (7), p.e69152-e69152

2013

Volltextzugriff (PDF)

Evaluating the Influence of a G-Quadruplex Prone Sequence on the Transactivation Potential by Wild-Type and/or Mutant P53 Family Proteins through a Yeast-Based Functional Assay

Genes, 2021-02, Vol.12 (2), p.277

2021

Volltextzugriff (PDF)

Dominant-negative features of mutant TP53 in germline carriers have limited impact on cancer outcomes

Molecular cancer research, 2011-03, Vol.9 (3), p.271-279

2011

Volltextzugriff (PDF)

Lymphocyte Doubling Time As A Key Prognostic Factor To Predict Time To First Treatment In Early-Stage Chronic Lymphocytic Leukemia

Frontiers in oncology, 2021-08, Vol.11, p.684621-684621

2021

Volltextzugriff (PDF)

p53 transactivation and the impact of mutations, cofactors and small molecules using a simplified yeast-based screening system

PloS one, 2011-06, Vol.6 (6), p.e20643

2011

Volltextzugriff (PDF)

Validation of a survival-risk score (SRS) in relapsed/refractory CLL patients treated with idelalisib-rituximab

Blood cancer journal (New York), 2020-09, Vol.10 (9), p.92, Article 92

2020

Volltextzugriff (PDF)

Potential Role of miRNAs in the Acquisition of Chemoresistance in Neuroblastoma

Journal of personalized medicine, 2021-02, Vol.11 (2), p.107

2021

Volltextzugriff (PDF)

NEAT1 Long Isoform Is Highly Expressed in Chronic Lymphocytic Leukemia Irrespectively of Cytogenetic Groups or Clinical Outcome

Non-coding RNA, 2020-03, Vol.6 (1), p.11

2020

Volltextzugriff (PDF)

Antitumor Effects of PRIMA-1 and PRIMA-1Met (APR246) in Hematological Malignancies: Still a Mutant P53-Dependent Affair?

Cells (Basel, Switzerland), 2021-01, Vol.10 (1), p.98

2021

Volltextzugriff (PDF)

The biological effects of N3-methyladenine

Journal of cellular biochemistry, 2004-02, Vol.91 (2), p.250-257

2004

Volltextzugriff (PDF)

Transcriptional Functionality of Germ Line p53 Mutants Influences Cancer Phenotype

Clinical cancer research, 2007-07, Vol.13 (13), p.3789-3795

2007

Volltextzugriff (PDF)

p53 mutants can often transactivate promoters containing a p21 but not Bax or PIG3 responsive elements

Oncogene, 2001-06, Vol.20 (27), p.3573-3579

2001

Volltextzugriff (PDF)

TP53 Mutants in the Tower of Babel of Cancer Progression

Human mutation, 2014-06, Vol.35 (6), p.689-701

2014

Volltextzugriff (PDF)

The TP53 website: an integrative resource centre for the TP53 mutation database and TP53 mutant analysis

Nucleic acids research, 2013-01, Vol.41 (Database issue), p.D962

2013

Volltextzugriff (PDF)

Amifostine (WR2721) restores transcriptional activity of specific p53 mutant proteins in a yeast functional assay

Oncogene, 2001-06, Vol.20 (27), p.3533-3540

2001

Volltextzugriff (PDF)

Gambogic acid counteracts mutant p53 stability by inducing autophagy

Biochimica et biophysica acta. Molecular cell research, 2017-02, Vol.1864 (2), p.382-392

2017

Volltextzugriff (PDF)

Tumour p53 mutations exhibit promoter selective dominance over wild type p53

Oncogene, 2002-03, Vol.21 (11), p.1641-1648

2002

Volltextzugriff (PDF)

Autophagy induced by SAHA affects mutant P53 degradation and cancer cell survival

Bioscience reports, 2019-02, Vol.39 (2)

2019

Volltextzugriff (PDF)

Characterization of the p53 mutants ability to inhibit p73β transactivation using a yeast-based functional assay

Oncogene, 2003-08, Vol.22 (34), p.5252-5260

2003

Volltextzugriff (PDF)

1 – 25 von 130

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(111)
Mit Volltextzugriff
(122)

Publikationsform

Artikel
(130)

Sprache

Englisch
(130)
Japanisch
(6)

Erscheinungsjahr

n.n

Thema

Science & Technology
(91)
Life Sciences & Biomedicine
(86)
Humans
(59)
Mutation
(39)
Tumor Suppressor Protein P53 - Genetics
(33)
Biochemistry & Molecular Biology
(31)
Biological And Medical Sciences
(30)
Oncology
(30)
Genetics & Heredity
(28)
Tumor Suppressor Protein P53 - Metabolism
(21)
Base Sequence
(20)
Molecular Sequence Data
(20)
Toxicology
(19)
Animals
(16)
Cell Biology
(16)
Hematology
(16)
P53
(16)
Saccharomyces Cerevisiae - Genetics
(16)
Female
(15)
Fundamental And Applied Biological Sciences. Psychology
(15)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Heterogeneity of TP53 Mutations and P53 Protein Residual Function in Cancer: Does It Matter?

The fading guardian: clinical relevance of TP53 null mutation in high-grade serous ovarian cancers

Time to first treatment and P53 dysfunction in chronic lymphocytic leukaemia: results of the O-CLL1 study in early stage patients

Mutant p53K120R expression enables a partial capacity to modulate metabolism

PRIMA-1 induces autophagy in cancer cells carrying mutant or wild type p53

Structure of p73 DNA-binding domain tetramer modulates p73 transactivation

P53 family members modulate the expression of PRODH, but not PRODH2, via intronic p53 response elements

Evaluating the Influence of a G-Quadruplex Prone Sequence on the Transactivation Potential by Wild-Type and/or Mutant P53 Family Proteins through a Yeast-Based Functional Assay

Dominant-negative features of mutant TP53 in germline carriers have limited impact on cancer outcomes

Lymphocyte Doubling Time As A Key Prognostic Factor To Predict Time To First Treatment In Early-Stage Chronic Lymphocytic Leukemia

p53 transactivation and the impact of mutations, cofactors and small molecules using a simplified yeast-based screening system

Validation of a survival-risk score (SRS) in relapsed/refractory CLL patients treated with idelalisib-rituximab

Potential Role of miRNAs in the Acquisition of Chemoresistance in Neuroblastoma

NEAT1 Long Isoform Is Highly Expressed in Chronic Lymphocytic Leukemia Irrespectively of Cytogenetic Groups or Clinical Outcome

Antitumor Effects of PRIMA-1 and PRIMA-1Met (APR246) in Hematological Malignancies: Still a Mutant P53-Dependent Affair?

The biological effects of N3-methyladenine

Transcriptional Functionality of Germ Line p53 Mutants Influences Cancer Phenotype

p53 mutants can often transactivate promoters containing a p21 but not Bax or PIG3 responsive elements

TP53 Mutants in the Tower of Babel of Cancer Progression

The TP53 website: an integrative resource centre for the TP53 mutation database and TP53 mutant analysis

Amifostine (WR2721) restores transcriptional activity of specific p53 mutant proteins in a yeast functional assay

Gambogic acid counteracts mutant p53 stability by inducing autophagy

Tumour p53 mutations exhibit promoter selective dominance over wild type p53

Autophagy induced by SAHA affects mutant P53 degradation and cancer cell survival

Characterization of the p53 mutants ability to inhibit p73β transactivation using a yeast-based functional assay

Suchergebnisse filtern